---
title: "Sanxin Medtec released its performance for the first half of the year, with a net profit attributable to the parent company of 115 million yuan, an increase of 8.35%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/252225647.md"
description: "Sanxin Medtec released its semi-annual report for 2025, with operating revenue of 761 million yuan, a year-on-year increase of 10.83%; net profit attributable to the parent company was 115 million yuan, a year-on-year increase of 8.35%. The net profit excluding non-recurring gains and losses was 103 million yuan, a year-on-year increase of 9.26%. The basic earnings per share were 0.2207 yuan, and the company plans to distribute a cash dividend of 1 yuan for every 10 shares to all shareholders. The company continues to expand its market and improve performance through a full product chain layout and moat advantages"
datetime: "2025-08-08T11:50:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/252225647.md)
  - [en](https://longbridge.com/en/news/252225647.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/252225647.md)
---

# Sanxin Medtec released its performance for the first half of the year, with a net profit attributable to the parent company of 115 million yuan, an increase of 8.35%

According to the Zhitong Finance APP, Sanxin Medtec (300453.SZ) released its semi-annual report for 2025, showing an operating income of 761 million yuan, a year-on-year increase of 10.83%. The net profit attributable to shareholders of the listed company was 115 million yuan, a year-on-year increase of 8.35%. The net profit attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 103 million yuan, a year-on-year increase of 9.26%. The basic earnings per share were 0.2207 yuan. In addition, it plans to distribute a cash dividend of 1 yuan (including tax) for every 10 shares to all shareholders.

During the reporting period, the company continuously expanded its domestic and international markets and improved the operating performance of its main products, leveraging its full product chain layout of "blood dialysis equipment + consumables" and the moat advantages of "quality + cost + service."

### Related Stocks

- [300453.CN](https://longbridge.com/en/quote/300453.CN.md)

## Related News & Research

- [13:41 ETUT Haslam Marks Decade in Major International Ranking's Top Five U.S. Public Schools](https://longbridge.com/en/news/286804132.md)
- [09:25 ETWasion Americas and Crytica Security Announce Partnership to Enhance Utility Security at the Grid Edge](https://longbridge.com/en/news/286921729.md)
- [US PJM grid can curb data center power usage in emergencies, Department of Energy says](https://longbridge.com/en/news/286949959.md)
- [Power prices are up 76% on America’s biggest grid, and a watchdog is pointing fingers](https://longbridge.com/en/news/286590257.md)
- [13:00 ETInventHelp Inventor Develops Modified Trash Can (CHK-5051)](https://longbridge.com/en/news/286801120.md)